This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garin-Chesa, P. Articles by Rettig, W. J. Search for Related Content PubMed PubMed Citation Articles by Garin-Chesa, P. Articles by Rettig, W. J.

American Journal of Pathology, Vol 134, 295-303, Copyright © 1989 by American Society for Investigative Pathology

REGULAR ARTICLES

Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems

P Garin-Chesa, HR Beresford, A Carrato-Mena, HF Oettgen, LJ Old, MR Melamed and WJ Rettig
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.

The rapidly expanding list of monoclonal antibodies (MAbs) to human cell surface antigens provides reagents to probe the biology of malignant melanoma and to develop new diagnostic and therapeutic approaches to this disease. The criteria used to select MAb-defined antigens as targets for passive immunotherapy or immunolocalization of melanoma include: 1) consistent antigen expression in melanomas, 2) restricted antigen distribution in normal tissues and nonmelanocytic tumors, and 3) cytotoxic activity of the MAb or MAb conjugates. The present study examined the tissue distribution of three prototype melanoma cell surface antigens, the Mr 57,000 glycoprotein (gp57) recognized by MAb A42, the GD3 ganglioside, and the mel-CSPG chondroitin sulfate proteoglycan. The avidin-biotin immunoperoxidase method was used to examine a large panel of normal tissues and over 150 malignant tumors. It was found that A42 has a highly restricted distribution in normal tissues and is expressed in subsets of melanomas and nonmelanocytic tumors. It was also found that GD3 and mel-CSPG are more widely distributed in normal tissues and among tumors than was thought previously. These immunohistochemical patterns provide an essential data base to evaluate the ongoing clinical trials employing MAbs to GD3 and mel-CSPG for the therapy and immunolocalization of melanomas, and they identify gp57 as a potential marker for subsets of normal and transformed melanocytic cells.

This article has been cited by other articles:

				A. M. Scott, F.-T. Lee, W. Hopkins, J. S. Cebon, J. M. Wheatley, Z. Liu, F. E. Smyth, C. Murone, S. Sturrock, D. MacGregor, et al. Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial J. Clin. Oncol., October 1, 2001; 19(19): 3976 - 3987. [Abstract] [Full Text]

				F.-T. Lee, A. Rigopoulos, C. Hall, K. Clarke, S. H. Cody, F. E. Smyth, Z. Liu, M. W. Brechbiel, N. Hanai, E. C. Nice, et al. Specific Localization, Gamma Camera Imaging, and Intracellular Trafficking of Radiolabelled Chimeric Anti-GD3 Ganglioside Monoclonal Antibody KM871 in SK-MEL-28 Melanoma Xenografts Cancer Res., June 1, 2001; 61(11): 4474 - 4482. [Abstract] [Full Text] [PDF]

				B. Wang, Y.-B. Chen, O. Ayalon, J. Bender, and A. Garen Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement PNAS, February 16, 1999; 96(4): 1627 - 1632. [Abstract] [Full Text] [PDF]